Follistatin 344Explore study findings
What a recent study record says about follistatin and age-related muscle loss
3 numbered sourcesSource years 2014, 2026
Peptides are short amino-acid chains connected by peptide bonds. Some influence cells by binding signaling proteins. Follistatin is a larger protein, and FST344 refers to the longer precursor that gives rise to the mature FST315 form. A 2026 trial registration explores an investigational gene therapy involving human follistatin in adults with age-related loss of muscle. The record offers recent context for follistatin research but does not specify an FST344 identity for the study intervention. [1] [2]
The registry describes an early, open-label study. It includes groups receiving follistatin gene therapy and a group receiving that intervention together with a separate intervention involving a blood vessel growth signal called VEGF. The primary purpose is to study safety and tolerability. Measures of muscle size and performance are exploratory. Because the groups are enrolled sequentially and are not randomly assigned, a difference between them could reflect characteristics of the groups as well as the intervention. [1]
Older trials in people with muscular dystrophy specifically identified an FST344 gene transfer intervention. It is useful to keep the specificity of those records separate from this newer one. They involve different populations and questions. A study of people with inherited muscle disease can provide historical context, but age-related muscle loss has different causes and patterns of progression. [1] [3]
As checked on November 8, 2026, the newer record listed the study as recruiting and had no posted results. Registration supplies a public description of what investigators intend to learn. Outcome data would be needed to evaluate what happened to participants, and identification of the protein form would matter to any claim specific to FST344. [1] [2]
Sources
Original works cited in this article. Links open the external record in a new tab.
